NCT03597295 · OUTCOME

AUC0-t of Retifanlimab

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · Source last updated 2025-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: day*mg/L
Interval / dispersion: Standard Deviation
Time frame: pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6

What was measured

AUC0-t was defined as the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.

Analysis population: PK Evaluable Population

Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Retifanlimab 500 mg	92

Source class 1

Values in day*mg/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Retifanlimab 500 mg	1950	594	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

AUC0-t was defined as the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.

dispersion Type

Standard Deviation

groups

param Type

MEAN

population Description

PK Evaluable Population

reporting Status

POSTED

time Frame

pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6

title

AUC0-t of Retifanlimab

type

SECONDARY

unit Of Measure

day*mg/L

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice